Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
NCT00089804 is registered in ClinicalTrials.gov with La Jolla Pharmaceutical Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
- Lead sponsor
- La Jolla Pharmaceutical Company
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 31, 2004
- Completion date
- February 28, 2009
- Enrollment
- 943 (actual)
- Sites
- 201
Conditions
As the registry lists them; a condition with its own page is linked.